XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1

Revenue (Tables)

3 Months Ended

Mar. 31, 2023

Revenue From Contract With Customer [Abstract]

Schedule of Disaggregated Revenue

The following table presents our disaggregated revenue for the periods presented (in thousands):

		Three Months Ended March 31,
		2023				2022
Immune Medicine revenue
Service revenue		$	7,102			$	7,113
Collaboration revenue			9,118				13,703
Total Immune Medicine revenue			16,220				20,816
MRD revenue
Service revenue			21,427				14,804
Regulatory milestone revenue			—				3,000
Total MRD revenue			21,427				17,804
Total revenue		$	37,647			$	38,620

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration